Last reviewed · How we verify
NCT03381209
The Effect of Sugammadex Given Based on Ideal, Actual or Adjusted Body Weight on Reversal of Rocuronium.
NA trial testing Sugammadex in Muscle Relaxation in 60 participants. Completed in 10 November 2017.
10 November 2017
Quick facts
| Lead sponsor | Ain Shams University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | health services research |
| Enrollment | 60 |
| Start date | 10 June 2017 |
| Primary completion | 10 November 2017 |
| Estimated completion | 10 November 2017 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Sugammadex — full drug profile →
Conditions studied
- Muscle Relaxation — all drugs for Muscle Relaxation →
Sponsor
Ain Shams University
Who can join
Adults 18 to 45, any sex, with Muscle Relaxation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is compare the reversal of rocuronium induced neuromuscular blockade in morbidly obese patients using three doses of sugammadex; based on ideal body weight, adjusted body weight, and actual body weight.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03381209
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sugammadex
Trials testing the same drug.
- NCT07477132 — A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 · Phase 4 · not yet recruiting
- NCT07271875 — Neuromuscular Blocking Agents on Gastrointestinal Function Following Colorectal Surgery · Phase 3 · not yet recruiting
- NCT07309393 — Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function · NA · recruiting
- NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
- NCT06575036 — Sugammadex Dose Finding Under Two Years Old · Phase 2 · not yet recruiting
Other recruiting trials for Muscle Relaxation
Currently open trials in the same condition.
- NCT06707532 — The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA) · NA · recruiting
- NCT05736744 — Effect of Magnesium Sulphate Pretreatment in Pediatric Abdominal Surgery · Phase 2, PHASE3 · recruiting
Other Ain Shams University trials
Trials by the same sponsor.
- NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
- NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
- NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
- NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
- NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03381209 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
- Last refreshed: 21 December 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03381209.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing